Slide 1: AIMIMMUNO.COM
AIMIMMUNO.COM NYSE AMERICAN:AIM
Slide 2: Forward-Looking Statements
Forward-Looking Statements Some of the statements included in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private
Slide 3: Investor Highlights
Investor Highlights We are an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders Lead program Ampligen® is an immuno-modulator with broad spectrum activity potentially applicable in multiple high-value i
Slide 4: Broad Oncology Pipeline Across High-Value Indications
AIM ImmunoTech Indications Ovarian Cancer (Advanced, Recurrent) Colorectal Cancer (Metastatic) Breast Cancer (Metastatic Triple-Negative) Ovarian Cancer (Advanced, Recurrent) Prostate Cancer (Early-Stage) Pancreatic Cancer Breast Cancer (Early-Stage Triple- Negative) Pancreatic Cancer Melanoma Appro
Slide 5: Extensive Viral and Immune System Disorder Pipeline
Extensive Viral and Immune System Disorder Pipeline vena DT a Viral Infections Combination: Interferon . CONID IS In Cancer tents oe ob od A ocer > Immune System Disorder enetee Approved in _ Severe CFS Single Agent Arena ME/CFS Single Agent Planning|rhase3: Confirmatory Trial y ong COVID-19 single
Slide 6: Proven Management Team
Proven Management Team Thomas K. Equels, M.S., J.D. iS Chief Executive Offi @ EAS erRn let Executive Icer BIOFLORIDA TS David R. Strayer, M.D. DREXEL UNIVERSITY Chief Scientific & Medical Officer sé College of Medicine GreenbergTraurig Hahnemann University HOSPITAL Peter W. Rodino III, J.D. Chief Op
Slide 7: Lead Program Ampligen® (rintatolimod)
Lead Program Ampligen® (rintatolimod) Significant Opportunity Across Multiple Disease Areas Generally well-tolerated with over 100,000 IV | mmu no-O ncology doses in humans Clinically tested in oncology as a single-agent therapeutic and in combination with other agents Virology Potential in oncology
Slide 8: Ampligen®: Immuno-Therapy Targeting Multiple Cancers with High-Unmet Need
Ampligen® Immuno-Therapy Targeting Multiple Cancers with High-Unmet Need
Slide 9: The Critical Unmet Need in Oncology
The Critical Unmet Need in Oncology Current Therapies are Effective but Only in a Subset of Patients, Leaving Many in Need of Better Options United States Statistics Ovarian Cancer’ Pancreatic Cancer’ Breast Cancer’ 21,410 13,770 60,430 48,220 281,550 43,600 New Cases Annually Deaths Annually New Ca
Slide 10: Ampligen® Induces a Wide Range of Immunologic and Anti-tumor Activities
Ampligen® Induces a Wide Range of Immunologic and Anti-tumor Activities Immuno-modulator that selectively activates TLR3 pathway - Exclusively activates TRIF adaptor and avoids MyD88 inflammatory pathway used by all other TLRs? Promotes selective attraction of CTLs (Teff) with concomitant increase i
Slide 11: Observed Complete Response in Subjects in Phase 1 Melanoma Study
Observed Complete Response in 2 of 9 Subjects in Phase 1 Melanoma Study Subject 1 Subject 2 Ampligen (300mg twice weekly) Ampligen (800mg twice weekly) Se is) Partial Response ¥ Partial Response TUMOR MASS a VOLUME OF RIGHT AXILLARY TUMOR MASS Complete Response v z Se t 1S) Q a 2 a (S) a = = {e) > 0
Slide 12: Synergistic Effects in Combination with Checkpoint Inhibitor, Anti-PD-L1
Synergistic Effects in Combination with Checkpoint Inhibitor, Anti-PD-L1 Pancreatic Cancer Mouse Model Synergistic Increase in Median Survival Synergistic Increase in Time to Progression — Control =exiBoritroil — 150 + Ampligen 150: > Anti-PD-L1 E > Control E > contro! s g Z 150 = Ampligen =z 150 SO
Slide 13: Increase in Median Survival Combining Ampligen® with Anti-PD-1
Increase in Median Survival Combining Ampligen® with Anti-PD-1 Colorectal Carcinoma Mouse Model = Ampligentanti-PD-1 = anti-PD-1 =“@ control z a > z 5 a o o = oe o UPMC LIFE CHANGING MEDICINE 13
Slide 14: Ongoing Clinical Studies Sponsored by UPMC
Phase 1/2 Advanced, Recurrent Ovarian Cancer Phase 1 portion completed Intraperitoneal chemo-immunotherapy Data published January 2022 PI: Dr. R. Edwards Ongoing Clinical Studies Sponsored by UPMC LIFE CHANGING MEDICINE Phase 2 Advanced, Recurrent Ovarian Cancer Enrollment and dosing ongoing Cisplat
Slide 15: Ongoing Clinical Studies Sponsored by Roswell Park
Ongoing Clinical Studies Sponsored by WeROSWELL Phase 2a Stage 4 Colorectal Cancer Metastatic, Liver Study completed Chemokine modulatory regimen Data being presented at AACR April 2022 Pl: Dr. P. Boland Phase 2 Early-Stage Prostate Cancer Enrollment and dosing ongoing Aspirin and Ampligen® with or
Slide 16: Promising Results From Early Access Program (EAP) Published in Cancers
Promising Results From Early Access Program (EAP) Published in Cancers Statistically Significant Increased Overall Survival Compared to Historical Controls in Treatment of Late-Stage Pancreatic Cancer Site: Erasmus University, The Netherlands, Eligibility: Adults with metastatic or locally conducted
Slide 17: Ampligen®: SARS-CoV-2 (COVID-19)
Ampligen’® SARS-CoV-2 (COVID-19)
Slide 18: Ampligen® May Mount a Potentially Broad-Spectrum Immune System Response Against SARS-CoV-2
Ampligen” May Mount a Potentially Broad-Spectrum Immune System Response Against SARS-CoV-2 (COVID-19) Targeting toll-like receptor 3 (TLR3) pathways, which are among the primary pathways for antiviral protection (uniquely targets TLR3 without activation of the inflammatory cytosolic helicases) Poten
Slide 19: Ongoing Phase 1/2 Study for Treatment of COVID-19 Cancer Patients
Ongoing Phase 1/2 Study for Treatment of COVID-19 Cancer Patients Actively Enrolling and Dosing Subjects Evaluating safety and effectiveness of intravenous Ampligen® to reduce replication of SARS-CoV-2 virus from upper airway in patients Next Steps: Planning intranasal study of Ampligen® to potentia
Slide 20: Ampligen®: Immune System Disorders (ISD)
Ampligen’® Immune System Disorders (ISD)
Slide 21: Ampligen® for the Treatment of ME/CFS
Ampligen’® for the Treatment of ME/CFS Only late-stage program in development in the U.S. for the treatment of ME/CFS, with an approval in Argentina Developing protocol for confirmatory Phase 3 trial, required for U.S. NDA Toll-Like Receptor 3 agonist which activates the innate immune system and ind
Slide 22: COVID-Induced Chronic Fatigue (Long COVID)
Fatigue | Brain Fog COVID-Induced Chronic Fatigue (Long COVID or ‘Long Haulers’) Amended ongoing open-label AMP-511 study in ME/CFS to include up to 20 long COVID subjects Currently treating long COVID subjects Chronic Illness Following COVID-19 Chronic illness following recovery is prevalent | Slee
Slide 23: Corporate Overview
Corporate Overview
Slide 24: Intellectual Property Portfolio — Market Exclusivity
Intellectual Property Portfolio — Market Exclusivity 44 Patents Worldwide Ampligen® 7 years market exclusivity following FDA approval 10 years market exclusivity following EMA approval 39 Pending Applications Orphan Drug Designation (FDA and EMA): Indications: U.S. — Pancreatic Cancer, Melanoma, ME/
Slide 25: Financial Snapshot
Financial Snapshot NYSE American: AIM Sufficient Capital to Fund Operations Through Multiple Key Clinical Milestones A7.38M Shares Outstanding? N Al M 1: As of September 30, 2021; 2: As of March 16, 2022, with a closing price of $0.84; 3: NYSE American ImmunoTech
Slide 26: Upcoming 2022 Milestones
Upcoming 2022 Milestones Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 Oncology Oncology Immune System Disorders ¥ tenuary 2022: Advanced Recurrent ‘Pancreatic Cancer Expressing TLR3_ + Report Interim Results from AMP- Ovarian Cancer: Phase 1 Publication of ‘eceptors: Publication of Preclinica an rogress tr
Slide 27: Investment Summary
Investment Summary Immuno-Pharma Company with Broad Pipeline Across Multiple High-Value Indications in Oncology, Virology and Immune-Deficiency Lead program Ampligen® has Leveraging external Growing body of data favorable safety profile and collaborators to fund potentially supports promising effica
Slide 28: AIMIMMUNO.COM
AIMIMMUNO.COM NYSE AMERICAN:AIM ImmunoTech «